Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (10): 987-992.doi: 10.3969/j.issn.1000-6621.2021.10.002
• Guideline·Standard·Consensus • Previous Articles Next Articles
Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis
Received:
2021-08-03
Online:
2021-10-10
Published:
2021-10-11
Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute , Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the study of early bactericidal activity of new anti-tuberculosis drugs[J]. Chinese Journal of Antituberculosis, 2021, 43(10): 987-992. doi: 10.3969/j.issn.1000-6621.2021.10.002
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.10.002
[1] |
Jindani A, Aber VR, Edwards EA, et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis, 1980, 121(6): 939-949. doi: 10.1164/arrd.1980.121.6.939.
doi: 10.1164/arrd.1980.121.6.939 |
[2] |
Donald PR, Sirgel FA, Venter A, et al. Early bactericidal activity of antituberculosis agents. Expert Rev Anti Infect Ther, 2003, 1(1): 141-155. doi: 10.1586/14787210.1.1.141.
doi: 10.1586/14787210.1.1.141 URL |
[3] |
Jindani A, Doré CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med, 2003, 167(10): 1348-1354. doi: 10.1164/rccm.200210-1125OC.
doi: 10.1164/rccm.200210-1125OC URL |
[4] |
Donald PR, Diacon AH. The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb), 2008, 88 Suppl 1:S75-S83. doi: 10.1016/S1472-9792(08)70038-6.
doi: 10.1016/S1472-9792(08)70038-6 URL |
[5] |
Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomized trial. Lancet, 2012, 380(9846): 986-993. doi: 10.1016/S0140-6736(12)61080-0.
doi: 10.1016/S0140-6736(12)61080-0 URL |
[6] |
Dooley KE, Miyahara S, von Groote-Bidlingmaier F, et al. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. Am J Respir Crit Care Med, 2020, 201(11): 1416-1424. doi: 10.1164/rccm.201910-1960OC.
doi: 10.1164/rccm.201910-1960OC URL |
[7] |
Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother, 2010, 54(8): 3402-3407. doi: 10.1128/AAC.01354-09.
doi: 10.1128/AAC.01354-09 URL |
[8] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427 URL |
[9] |
Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother, 2008, 52(8): 2831-2835. doi: 10.1128/AAC.01204-07.
doi: 10.1128/AAC.01204-07 pmid: 18505852 |
[10] |
Paramasivan CN, Herbert D, Umapathy KC, et al. Early bactericidal action of pulsed exposure to rifampicin, ethambutol, isoniazid & pyrazinamide in pulmonary tuberculosis patients. Indian J Med Res, 1994, 100: 1-4.
pmid: 7927544 |
[11] |
Sirgel FA, Donald PR, Odhiambo J, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother, 2000, 45(6): 859-870. doi: 10.1093/jac/45.6.859.
doi: 10.1093/jac/45.6.859 URL |
[12] |
Johnson JL, Hadad DJ, Boom WH, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis, 2006, 10(6): 605-612.
pmid: 16776446 |
[13] |
Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity of antituberculosis agents. Eur J Clin Microbiol Infect Dis, 2010, 29(12): 1561-1565. doi: 10.1007/s10096-010-1043-7.
doi: 10.1007/s10096-010-1043-7 URL |
[14] |
McAulay K, Saito K, Warrier T, et al. Differentially detectable Mycobacterium tuberculosis cells in sputum from treatment-naive subjects in Haiti and their proportionate increase after initiation of treatment. mBio, 2018, 9(6): e02192-18. doi: 10.1128/mBio.02192-18.
doi: 10.1128/mBio.02192-18 |
[15] |
Epstein MD, Schluger NW, Davidow AL, et al. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest, 1998, 113(2): 379-386. doi: 10.1378/chest.113.2.379.
doi: 10.1378/chest.113.2.379 pmid: 9498955 |
[16] |
Hesseling AC, Walzl G, Enarson DA, et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. Int J Tuberc Lung Dis, 2010, 14(5): 560-570.
pmid: 20392348 |
[17] |
Pheiffer C, Carroll NM, Beyers N, et al. Time to detection of Mycobacterium tuberculosis in BACTEC systems as a viable alternative to colony counting. Int J Tuberc Lung Dis, 2008, 12(7): 792-798.
pmid: 18544206 |
[18] |
Abe C, Hosojima S, Fukasawa Y, et al. Comparison of MB-Check,BACTEC, and egg-based media for recovery of mycobacteria. J Clin Microbiol, 1992, 30(4): 878-881. doi: 10.1128/jcm.30.4.878-881.1992.
doi: 10.1128/jcm.30.4.878-881.1992 pmid: 1572974 |
[19] |
Chew WK, Lasaitis RM, Schio FA, et al. Clinical evaluation of the mycobacteria growth indicator tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of mycobacterium species. J Med Microbiol, 1998, 47(9): 821-827. doi: 10.1099/00222615-47-9-821.
doi: 10.1099/00222615-47-9-821 pmid: 9736164 |
[20] |
Pfyffer GE, Welscher HM, Kissling P, et al. Comparison of the mycobacteria growth indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol, 1997, 35(2): 364-368. doi: 10.1128/jcm.35.2.364-368.
doi: 10.1128/jcm.35.2.364-368.1997 pmid: 9003597 |
[21] |
Somoskövi A, Magyar P. Comparison of the mycobacteria growth indicator tube with MB redox, Löwenstein-Jensen, and Middlebrook 7H11 media for recovery of mycobacteria in clinical specimens. J Clin Microbiol, 1999, 37(5): 1366-1369. doi: 10.1128/JCM.37.5.1366-1369.1999.
doi: 10.1128/JCM.37.5.1366-1369.1999 pmid: 10203488 |
[22] |
Diacon AH, Dawson R, du Bois J, et al. Phase Ⅱ dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother, 2012, 56(6): 3027-3031. doi: 10.1128/AAC.06125-11.
doi: 10.1128/AAC.06125-11 URL |
[23] |
Diacon AH, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis, 2011, 15(7): 949-954. doi: 10.5588/ijtld.10.0616.
doi: 10.5588/ijtld.10.0616 pmid: 21682970 |
[24] |
Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother, 2013, 57(5): 2199-2203. doi: 10.1128/AAC.02243-12.
doi: 10.1128/AAC.02243-12 URL |
[25] |
Diacon AH, Maritz JS, Venter A, et al. Time toliquid culture positivity can substitute for colony counting on agar plates in early bactericidal activity studies of antituberculosis agents. Clin Microbiol Infect, 2012, 18(7): 711-717. doi: 10.1111/j.1469-0691.2011.03626.x.
doi: 10.1111/j.1469-0691.2011.03626.x URL |
[26] |
Fenner F. The enumeration of viable tubercle bacilli by surface plate counts. Am Rev Tuberc, 1951, 64(4): 353-380. doi: 10.1164/art.1951.64.4.353.
doi: 10.1164/art.1951.64.4.353 |
[27] |
Walsh KF, McAulay K, Lee MH, et al. Early Bactericidal Activity Trial of Nitazoxanide for Pulmonary Tuberculosis. Antimicrob Agents Chemother, 2020, 64(5): e01956-19. doi: 10.1128/AAC.01956-19.
doi: 10.1128/AAC.01956-19 |
[28] |
Diacon AH, Donald PR. The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther, 2014, 12(2): 223-237. doi: 10.1586/14787210.2014.870884.
doi: 10.1586/14787210.2014.870884 URL |
[29] |
Sirgel F, Venter A, Mitchison D. Sources of variation in studies of the early bactericidal activity of antituberculosis drugs. J Antimicrob Chemother, 2001, 47(2): 177-182. doi: 10.1093/jac/47.2.177.
doi: 10.1093/jac/47.2.177 URL |
[30] |
Chan SL, Yew WW, Ma WK, et al. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis. Tuber Lung Dis, 1992, 73(1): 33-38. doi: 10.1016/0962-8479(92)90077-W.
doi: 10.1016/0962-8479(92)90077-W URL |
[31] |
Donald PR, Sirgel FA, Botha FJ, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 895-900. doi: 10.1164/ajrccm.156.3.9609132.
doi: 10.1164/ajrccm.156.3.9609132 URL |
[32] |
Hafner R, Cohn JA, Wright DJ, et al. Early bactericidalactivity of isoniazid in pulmonary tuberculosis. Optimization of methodology.The DATRI008 Study Group. Am J Respir Crit Care Med, 1997, 156(3 Pt 1): 918-923. doi: 10.1164/ajrccm.156.3.9612016.
doi: 10.1164/ajrccm.156.3.9612016 URL |
[33] |
Tessema B, Beer J, Emmrich F, et al. Rate ofrecovery of Mycobacterium tuberculosis from frozen acid-fast-bacillussmear-positive sputum samples subjected to long-term storage in Northwest Ethiopia. J Clin Microbiol, 2011, 49(7): 2557-2561. doi: 10.1128/JCM.00059-11.
doi: 10.1128/JCM.00059-11 pmid: 21562105 |
[34] |
Chambers HF, Kocagöz T, Sipit T, et al. Activity of amoxicillin/clavulanate in patients with tuberculosis. Clin Infect Dis, 1998, 26(4): 874-877. doi: 10.1086/513945.
doi: 10.1086/513945 pmid: 9564467 |
[35] |
Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med, 2001, 1: 2. doi: 10.1186/1471-2466-1-2.
doi: 10.1186/1471-2466-1-2 pmid: 11737875 |
[36] |
Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J, 2008, 2: 59-76. doi: 10.2174/1874279300802010059.
doi: 10.2174/1874279300802010059 pmid: 23814629 |
[37] |
Mitchison DA. The action of antituberculosis drugs in short-course chemotherapy. Tubercle, 1985, 66(3): 219-225. doi: 10.1016/0041-3879(85)90040-6.
doi: 10.1016/0041-3879(85)90040-6 pmid: 3931319 |
[38] |
Sirgel FA, Botha FJ, Parkin DP, et al. The early bactericidal activity of rifabutin inpatients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother, 1993, 32(6): 867-875. doi: 10.1093/jac/32.6.867.
doi: 10.1093/jac/32.6.867 URL |
[39] |
Kolwijck E, Mitchell M, Venter A, et al. Short-term storage does not affect the quantitative yield of Mycobacterium tuberculosis in sputum in early-bactericidal-activity studies. J Clin Microbiol, 2013, 51(4): 1094-1098. doi: 10.1128/JCM.02751-12.
doi: 10.1128/JCM.02751-12 pmid: 23345289 |
[40] |
Svensson RJ, Svensson EM, Aarnoutse RE, et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations. J Infect Dis, 2018, 218(6): 991-999. doi: 10.1093/infdis/jiy242.
doi: 10.1093/infdis/jiy242 pmid: 29718390 |
[41] | Botha FJ, Sirgel FA, Parkin DP, et al. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J, 1996, 86(2): 155-158. |
[42] |
Kennedy N, Fox R, Kisyombe GM, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. Am Rev Respir Dis, 1993, 148(6 Pt 1): 1547-1551. doi: 10.1164/ajrccm/148.6_Pt_1.1547.
doi: 10.1164/ajrccm/148.6_Pt_1.1547 URL |
[1] | Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866. |
[2] | Beijing Chest Hospital, Capital Medical University, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on the therapeutic drug monitoring of anti-tuberculosis drugs [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 867-873. |
[3] | Chinese Antituberculosis Association. Expert consensus on detection and preventive treatment of latent tuberculosis infection in high-risk population [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 874-878. |
[4] | ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882. |
[5] | PANG Yu, GAO Xing-hui, TANG Yi-wei, GAO Meng-qiu. Host immune responses-based methods for laboratory diagnosis and clinical application of tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 883-892. |
[6] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[7] | WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. |
[8] | SHI Wen-hui, CHU Nai-hui. Resistance to fluoroquinolones and the influencing factors in patients with drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 905-909. |
[9] | ZHANG Ting, SU Qian, WU Cheng-guo, WANG Qing-ya, LEI Rong-rong, CHEN Jian. Analysis of direct medical costs and influencing factors of pulmonary tuberculosis patients in Chongqing [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 910-915. |
[10] | ZHAO Xiu-juan, MO Jing-lian, SUN Tao, LIU Lin, ZHONG Ye-teng, PEI Hua, XIA Qian-feng. Prevalence and correlated factors of drug-resistant pulmonary tuberculosis admitted to the designated medical institutions in Hainan Province from 2015 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 916-923. |
[11] | LIN Jian, LIN Shu-fang, DAI Zhi-song, ZHAO Yong, ZHOU Yin-fa, ZHANG Tian-lin, WEI Shu-zhen. Analysis of the drug resistance surveillance results of Mycobacterium tuberculosis in Fujian Province from 2016 to 2019 [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 924-928. |
[12] | LI Ting, HE Jin-ge, XIA Lan, CHEN Chuang, XIAO Yue, LU Jia, WANG Dan-xia. The impact of the COVID-19 epidemic on tuberculosis notification in Sichuan Province [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 929-938. |
[13] | YI Yi-hang, YU Rong, SHI Guo-min, MA Xiao-hua, XIAO Si-fang, SHUI Jian, FAN Ren-hua, XIANG Yan-gen. Analysis of the composition and phenotypes of intestinal flora in primary bacteriologically-confirmed pulmonary tuberculosis patients based on high-throughput sequencing of 16S rRNA V4 region [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 939-946. |
[14] | ZHOU Ying-yu, FU Lei, ZHANG Wei-yan, WANG Bin, CHEN Xi, LU Yu, CHEN Xiao-you. Analysis and comparative study on the virulence of several drug-resistant Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 952-960. |
[15] | MA Ting-ting, REN Fei, MA Jin-bao, YANG Han. Resistance of prothionamided and sodium aminosalicylate among isoniazid resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 961-964. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||